Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

SER-287 & Ulcerative Colitis (UC)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Clinical data

The double-blind phase Ib treatment trial NCT02618187 - SER-287 vs SER-287 + Vancomycin & Ulcerative colitis (UC) revealed that SER-287 was found to be just as safe and tolerable as a placebo (1)

The phase IIb, randomized, double-blind, placebo-controlled, multiple dose, multicenter treatment trial NCT03759041 - ECO-RESET - SER-287 & Ulcerative Colitis (UC) revealed that SER-287 did not succeed in enhancing outcomes in a phase II trial for ulcerative colitis (2)

References

(1) Henn et al. 2021 Gastroenterology 160: 115-27
(2) Mullard et al. 2021 Nat Rev Drug Discov 20: 658

see also:
[Probiotics (living agents) & U…

References (Sources)

A Phase 1b safety study of SER-287, a sporebased microbiome therapeutic, for active mild to moderate ulcerative colitis
Henn et al. 2021 Gastroenterology 160: 115-27
First microbiome-based drug clears phase III, in clinical trial turnaround
Garber 2020 Nat. Rev. Drug Discov. 19: 655–656

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!